Bone Remodeling and Thyroid Function
| Autor: | Velimir Altabas, Maja Berković, Branko Bečejac, Miljenko Solter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
endocrine system
endocrine system diseases Koštana pregradnja - fiziologija Kost i kosti - fiziologija Kost i kosti - metabolizam Hormoni štitnjače - fiziologija Hormoni štitnjače -nedostatak Biliopancreatic diversion – methods Obesity morbid – surgery Gastrectomy – methods Body weight Weight loss Case report |
| Zdroj: | Acta clinica Croatica Volume 46 Issue 1 |
| ISSN: | 1333-9451 0353-9466 |
| Popis: | Many diseases are associated with more rapid bone loss and an increased risk of osteoporosis and fractures. Both hyperthyroidism and hypothyroidism as well as use of thyroid hormones or thyrosuppressant treatment influence bone turnover rates and may alter the risk of future fractures. Markers of bone remodeling are good indicators to determine bone turnover rates and potential bone loss, and correlate well with thyroid hormone levels. Untreated hyperthyroidism accelerates bone turnover resulting in net bone loss, while untreated hypothyroidism in adult humans slows down bone turnover resulting in net bone gain. In both cases, damage in bone microarchitecture occurs, leading to an increased relative risk of fractures. Effective therapies for both states are available, and in ideal case, full recovery of mineralized tissue may occur over time. Controversies are still present in patients receiving suppressive thyroxin treatment for thyroid carcinoma. It seems that suppressed thyroid-stimulating hormone with normal levels of peripheral thyroid hormones may increase the relative fracture risk in postmenopausal but not in premenopausal women. However, the exact molecular mechanisms of thyroid hormone and thyroid-stimulating hormone action on bone are not completely understood yet. Mnoge bolesti su udružene s ubrzanom koštanom razgradnjom i povećanim rizikom od nastanka osteoporoze. Poremećaji funkcije štitne žlijezde, kao i liječenje hormonima štitnjače, mogu utjecati na brzinu koštane pregradnje te utjecati na rizik od nastanka fraktura. Biljezi koštane pregradnje su dobri pokazatelji za praćenje brzine koštane pregradnje i utvrđivanje rizika od mogućeg gubitka koštane mase, i dobro koreliraju s razinom hormona štitnjače. Neliječena hipertireoza ubrzava koštanu pregradnju dovodeći do gubitka koštane mase, dok neliječena hipotireoza u ljudi usporava koštanu pregradnju te dovodi do pretjerane mineralizacije skeleta. U oba slučaja dolazi do narušavanja mikroarhitekture i povećanog rizika od nastanka fraktura. Djelotvorna je terapija dostupna za oba poremećaja rada štitne žlijezde i u idealnim će slučajevima dovesti do potpunog oporavka mineraliziranih tkiva. Nesuglasje postoji oko bolesnika koji dobivaju tireosupresivnu terapiju prilikom liječenja karcinoma štitnjače. Izgleda da suprimirane razine TSH i normalne razine perifernih hormona štitnjače mogu povećati relativni rizik za nastanak fraktura u žena nakon menopauze, ali ne i prije nje. Točni molekularni mehanizmi djelovanja hormona štitnjače i TSH na kosti još nisu do kraja rasvijetljeni. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|